Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
Jose AguarelesPaula Villares FernándezCarles FornéEva María Martí-BallesterosVirginia Pradillo FernándezGabriel Sotres-FernandezAdolfo de la Fuente-BurgueraCarolina Navarro-San FranciscoLuis Miguel Buzón-MartínTeresa García-DelangueFrancesco Tommaso AielloDaniel Carnevali-RuizRaquel LlorisXavier Erik Luepke-EstefanJosé Antonio López-MartínJosé María JimenoAna García-CasasPablo Guisado-VascoPublished in: Infectious diseases (London, England) (2024)
Patients with haematological malignancies appear to be at a heightened risk for delayed SARS-CoV-2 clearance and subsequent clinical complications. These findings support plitidepsin as a well-tolerated treatment in this high-risk group. A phase II clinical trial (NCT05705167) is ongoing to evaluate plitidepsin as an antiviral drug in this population.KEY POINTSHaematological patients face an increased risk for severe COVID-19.Anti-CD20 therapies could increase fatal outcomes in COVID-19 patients.Persistent viral replication is increased in immunocompromised patients.Plitidepsin does not lead to new serious adverse events in immunocompromised patients.
Keyphrases
- sars cov
- end stage renal disease
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- phase ii
- peritoneal dialysis
- open label
- emergency department
- randomized controlled trial
- metabolic syndrome
- adipose tissue
- intensive care unit
- skeletal muscle
- insulin resistance
- patient reported outcomes
- study protocol
- phase iii
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation